Cargando…

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study

Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Posso, Margarita, Corominas, Josep M., Serrano, Laia, Román, Marta, Torá‐Rocamora, Isabel, Domingo, Laia, Romero, Anabel, Quintana, María Jesús, Vernet‐Tomas, María, Baré, Marisa, Vidal, Carmen, Sánchez, Mar, Saladié, Francina, Natal, Carmen, Ferrer, Joana, Servitja, Sònia, Sala, María, Castells, Xavier, Burón, Andrea, Rodríguez‐Arana, Ana, Romero, Ana, Vernet, Mar, Andreu, Xavier, Milà, Núria, López‐Vilaró, Laura, Fernández‐Somoano, Ana, Galceran, Jaume, Espinàs, Josep Alfons
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463091/
https://www.ncbi.nlm.nih.gov/pubmed/28470951
http://dx.doi.org/10.1002/cam4.1080
_version_ 1783242639724773376
author Posso, Margarita
Corominas, Josep M.
Serrano, Laia
Román, Marta
Torá‐Rocamora, Isabel
Domingo, Laia
Romero, Anabel
Quintana, María Jesús
Vernet‐Tomas, María
Baré, Marisa
Vidal, Carmen
Sánchez, Mar
Saladié, Francina
Natal, Carmen
Ferrer, Joana
Servitja, Sònia
Sala, María
Castells, Xavier
Burón, Andrea
Rodríguez‐Arana, Ana
Romero, Ana
Vernet, Mar
Andreu, Xavier
Milà, Núria
López‐Vilaró, Laura
Fernández‐Somoano, Ana
Galceran, Jaume
Espinàs, Josep Alfons
author_facet Posso, Margarita
Corominas, Josep M.
Serrano, Laia
Román, Marta
Torá‐Rocamora, Isabel
Domingo, Laia
Romero, Anabel
Quintana, María Jesús
Vernet‐Tomas, María
Baré, Marisa
Vidal, Carmen
Sánchez, Mar
Saladié, Francina
Natal, Carmen
Ferrer, Joana
Servitja, Sònia
Sala, María
Castells, Xavier
Burón, Andrea
Rodríguez‐Arana, Ana
Romero, Ana
Vernet, Mar
Andreu, Xavier
Milà, Núria
López‐Vilaró, Laura
Fernández‐Somoano, Ana
Galceran, Jaume
Espinàs, Josep Alfons
author_sort Posso, Margarita
collection PubMed
description Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case–control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow‐up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs’ specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with >90% of ER expression had a higher risk of breast cancer (OR = 2.63; 95% CI: 1.26–5.51) than women with ≤70% of ER expression. Similarly, women with >80% of PR expression had a higher risk of breast cancer (OR = 2.22; 95% CI: 1.15–4.27) than women with ≤40% of PR expression. Women with proliferative disease and ≥1% of Ki67 expression had a nonsignificantly increased risk of breast cancer (OR = 1.16; 95% CI: 0.46–2.90) than women with <1% of Ki67 expression. A high expression of ER and PR in BBD is associated with an increased risk of subsequent breast cancer. In proliferative disease, high Ki67 expression may also have an increased risk. This information is helpful to better characterize BBD and is one more step toward personalizing the clinical management of these women.
format Online
Article
Text
id pubmed-5463091
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54630912017-06-09 Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study Posso, Margarita Corominas, Josep M. Serrano, Laia Román, Marta Torá‐Rocamora, Isabel Domingo, Laia Romero, Anabel Quintana, María Jesús Vernet‐Tomas, María Baré, Marisa Vidal, Carmen Sánchez, Mar Saladié, Francina Natal, Carmen Ferrer, Joana Servitja, Sònia Sala, María Castells, Xavier Burón, Andrea Rodríguez‐Arana, Ana Romero, Ana Vernet, Mar Andreu, Xavier Milà, Núria López‐Vilaró, Laura Fernández‐Somoano, Ana Galceran, Jaume Espinàs, Josep Alfons Cancer Med Cancer Prevention Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), progesterone receptor (PR), and Ki67 expression stratify risk of breast cancer in screened women with BBD. We conducted a nested case–control study. Women with breast cancer and prior BBDs (86 cases) were matched to women with prior BBDs who were free from breast cancer (172 controls). The matching factors were age at BBD diagnosis, type of BBD, and follow‐up time since BBD diagnosis. ER, PR, and Ki67 expression were obtained from BBDs’ specimens. Conditional logistic regression was used to estimate odds ratios (ORs), and 95% confidence intervals (CIs) of breast cancer risk according to ER, PR, and Ki67 expression. Women with >90% of ER expression had a higher risk of breast cancer (OR = 2.63; 95% CI: 1.26–5.51) than women with ≤70% of ER expression. Similarly, women with >80% of PR expression had a higher risk of breast cancer (OR = 2.22; 95% CI: 1.15–4.27) than women with ≤40% of PR expression. Women with proliferative disease and ≥1% of Ki67 expression had a nonsignificantly increased risk of breast cancer (OR = 1.16; 95% CI: 0.46–2.90) than women with <1% of Ki67 expression. A high expression of ER and PR in BBD is associated with an increased risk of subsequent breast cancer. In proliferative disease, high Ki67 expression may also have an increased risk. This information is helpful to better characterize BBD and is one more step toward personalizing the clinical management of these women. John Wiley and Sons Inc. 2017-05-04 /pmc/articles/PMC5463091/ /pubmed/28470951 http://dx.doi.org/10.1002/cam4.1080 Text en © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Posso, Margarita
Corominas, Josep M.
Serrano, Laia
Román, Marta
Torá‐Rocamora, Isabel
Domingo, Laia
Romero, Anabel
Quintana, María Jesús
Vernet‐Tomas, María
Baré, Marisa
Vidal, Carmen
Sánchez, Mar
Saladié, Francina
Natal, Carmen
Ferrer, Joana
Servitja, Sònia
Sala, María
Castells, Xavier
Burón, Andrea
Rodríguez‐Arana, Ana
Romero, Ana
Vernet, Mar
Andreu, Xavier
Milà, Núria
López‐Vilaró, Laura
Fernández‐Somoano, Ana
Galceran, Jaume
Espinàs, Josep Alfons
Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title_full Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title_fullStr Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title_full_unstemmed Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title_short Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
title_sort biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463091/
https://www.ncbi.nlm.nih.gov/pubmed/28470951
http://dx.doi.org/10.1002/cam4.1080
work_keys_str_mv AT possomargarita biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT corominasjosepm biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT serranolaia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT romanmarta biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT torarocamoraisabel biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT domingolaia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT romeroanabel biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT quintanamariajesus biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT vernettomasmaria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT baremarisa biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT vidalcarmen biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT sanchezmar biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT saladiefrancina biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT natalcarmen biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT ferrerjoana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT servitjasonia biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT salamaria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT castellsxavier biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT buronandrea biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT rodriguezaranaana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT romeroana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT vernetmar biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT andreuxavier biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT milanuria biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT lopezvilarolaura biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT fernandezsomoanoana biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT galceranjaume biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy
AT espinasjosepalfons biomarkersexpressioninbenignbreastdiseasesandriskofsubsequentbreastcanceracasecontrolstudy